Governance
Investors

Pipeline

NidlegyTM

Preclinical

Phase I

Phase II

Phase III

Stage III B,C Melanoma (EU)

–

–

–

–

Stage III B,C Melanoma (US)

–

–

–

–

Stage IV Melanoma 

–

–

–

–

Nonmelanoma Skin Cancer (BCC/SCC)

–

–

–

–

Fibromun

Preclinical

Phase I

Phase II

Phase III

+ Doxorubicin – 1st line Soft-Tissue Sarcoma (EU)

–

–

–

–

+ Doxorubicin – 1st line Leiomyosarcoma (US)

–

–

–

–

+ Dacarbazine – pre-treated Soft-Tissue Sarcoma (EU)

–

–

–

–

Monotherapy – recurrent Glioma (CH)

–

–

–

–

+ Lomustine – recurrent Glioma (EU)

–

–

–

–

+ Radiation + Temozolomide – 1st line Glioma (EU)

–

–

–

–

Darleukin

Preclinical

Phase I

Phase II

Phase III

+ Radiation – Non-Small Cell Lung Cancer

–

–

–

–

Dodekin

Preclinical

Phase I

Phase II

Phase III

Various Solid Tumors

–

–

–

–

Dekavil

Preclinical

Phase I

Phase II

Phase III

Chronic Inflammation

–

–

–

–

ABBV-022

Preclinical

Phase I

Phase II

Phase III

Ulcerative Colitis

–

–

–

–

Onco IX

Preclinical

Phase I

Phase II

Phase III

Renal Cell Carcinoma

–

–

–

–

Onco FAP

Preclinical

Phase I

Phase II

Phase III

Various Solid Tumors

–

–

–

–

FAP-IL12

Preclinical

Phase I

Phase II

Phase III

Undisclosed

–

–

–

–

Tripokin

Preclinical

Phase I

Phase II

Phase III

Undisclosed

–

–

–

–